

Supplementary Information

**Epoc group: transformable protecting
group with gold(III)-catalyzed
fluorene formation**

Tomoya Yamamoto^a, Tsung-Che Chang^a, Katsunori Tanaka^{a,b,c,*}

^a Biofunctional Synthetic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan

^b Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo, 152-8552, Japan

^c Biofunctional Chemical Laboratory, A. Butlerov Institute of Chemistry, Kazan Federal University, 18 Kremlyovskaya street, Kazan, 420008, Russia

*Corresponding Author E-mail: kotzenori@riken.jp

Table of Contents


1. Synthetic protocols and characterizations.....	3
1.1 Material.....	3
1.2 Synthesis of Epoc-introducing reagents	3
1.3 Introduction and deprotection Epoc group	7
1.4 Study for orthogonal deprotections	11
1.5 Synthesis of Epoc-protected amino acids for solid-phase peptide synthesis	19
2. Solvent screening for the fluorene formation of Epoc group	20
2.1 HPLC product standard curves and calibration.....	20
2.2 Condition screening for fluorene formation	21
2.3 Fluorene formation under aqueous conditions.....	25
3. Solid-phase peptide synthesis.....	25
3.1 Test for Epoc transformation on resin	25
3.2 Synthesis of branched peptides	29
4. References	32
5. NMR spectra.....	33

1. Synthetic protocols and characterizations

1.1 Material

All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), Kanto Chemical Co. Inc. (Tokyo, Japan), Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan), FUJIFILM Wako Pure Chemical Corp. (Osaka, Japan) or Watanabe Chemical Industries (Hiroshima, Japan) without further purification. Experiments dealing with air- and moisture-sensitive compounds were conducted under an atmosphere of dry nitrogen. TLC analyses (F-254) were performed with 60 Å silica gel from Merck. ^1H and ^{13}C NMR spectra were measured on a JEOL (AL400 400 MHz) instrument with the solvent peaks as internal standards: 7.26 and δC 77.16 for CDCl_3 , δH 3.31 and δC 49.0 for CD_3OD , δH 2.50 and δC 39.52 for DMSO-d_6 , δH 2.05 and δC 29.84 for Acetone- d_6 . Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, br = broad. For ^{13}C NMR, the chemical shift shown with [] is the multiple peaks from same carbons derived from diastereomers. High-resolution mass spectra (HRMS) were obtained on a Bruker MicroTOF-QIII spectrometer® by electron spray ionization time-of-flight (ESI-TOF-MS).


1.2 Synthesis of Epoc-introducing reagents



Compound **1'**

To a stirred suspension of 1-bromo-2-iodobenzene (2.21 mL, 17.7 mmol, 1.0 Eq), copper(I) iodide (336.6 mg, 1.77 mmol, 0.1 Eq) and Bis(triphenylphosphine)palladium(II) dichloride (620.3 mg, 0.884 mmol, 0.05 Eq) in THF/ Et_3N = 1/1 (degassed by performing four freeze-pump-thaw cycles) was added (triisopropylsilyl)acetylene (5.90 mL, 26.5 mmol, 1.5 Eq). The mixture was stirred at room temperature for 1 hour and filtered with Celite. The obtained filtrate was evaporated in a vacuum. The product was purified via flash column chromatography (SiO_2 , Hexane 100%) to yield compound **1'** as a colorless oil (7.66 g, quant.).


Compound **1'**: R_f = 0.70 (Hexane/ EtOAc = 9/1); ^1H NMR (400 MHz, CDCl_3) δ 7.57 (1H, dd, J = 8.0, 1.2 Hz), 7.50 (1H, dd, J = 8.0, 1.6 Hz), 7.24 (1H, td, J = 8.0, 1.2 Hz), 7.15 (1H, td, J = 8.0, 1.6 Hz), 1.16 (brs, 21H); ^{13}C NMR (100 MHz, CDCl_3) δ 134.0, 132.5, 129.5, 127.0, 125.9, 125.8, 104.9, 96.3, 18.8, 11.4.



Compound 2

To a stirred solution of compound **1'** (17.7 mmol) in THF (45 mL) was added *n*BuLi (12.4 mL, 1.57 M in Hexane, 19.4 mmol, 1.1 Eq) at -78 °C. The mixture solution was stirred for 1.5 hour at -78 °C, and 5-methyl-2-furaldehyde (1.93 mL, 19.4 mmol, 1.1 Eq) was subsequently added. The mixture was warmed to room temperature and stirred for 1 hour. Saturated aqueous NH₄Cl was added to the mixture. The product was extracted to Et₂O. Organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The product was purified via flash column chromatography (SiO₂, EtOAc: Hex 0:100 ~ 4:96) to yield compound **2** as a yellow oil (5.84 g, 15.83 mmol, 90% in 2 steps).


Compound **2**: R_f = 0.60 (Hexane/EtOAc = 3/1); ¹H NMR (400 MHz, CDCl₃) δ 7.62 (1H, d, *J* = 7.6 Hz), 7.49 (1H, dd, *J* = 7.6, 1.2 Hz), 7.37 (1H, td, *J* = 7.6, 1.2 Hz), 7.26 (1H, td, *J* = 7.6, 1.2 Hz), 6.24 (1H, d, *J* = 5.2 Hz), 5.84 (1H, dd, *J* = 3.2, 0.8 Hz), 5.81 (1H, d, *J* = 3.2 Hz), 2.70 (1H, d, *J* = 5.2 Hz), 2.26 (3H, s), 1.08 (21H, s); ¹³C NMR (100 MHz, CDCl₃) δ 153.5, 152.3, 143.0, 133.0, 128.8, 127.6, 126.5, 121.7, 108.9, 106.3, 104.4, 96.7, 68.6, 18.7, 13.7, 11.3; HRMS (ESI, pos): calcd. for C₂₃H₃₂NaO₂Si [M+Na]⁺: 391.2064 found: 391.2058.



Compound 3

To a stirred solution of compound **2** (5.54 g, 15.0 mmol) in EtOAc (50 mL) was added 2-iodoxybenzoic acid (12.9 g, 18.0 mmol, 39 wt% purity, 1.2 Eq). The mixture was heated to 70 °C and stirred for 3.5 h. After cooled to room temperature, the mixture was filtered with Celite and the filtrate was evaporated. The obtained product was purified via flash column chromatography (SiO₂, EtOAc: Hex 1:99 ~ 5:95) to yield compound **3** as a yellow oil (4.58 g, 12.5 mmol, 83%).

Compound **3**: R_f = 0.36 (Hexane/EtOAc = 9/1); ¹H NMR (400 MHz, CDCl₃): δ 7.55 (1H, d, *J* = 8.0, 1.6 Hz), 7.46-7.36 (3H, m), 6.89 (1H, d, *J* = 3.6 Hz), 6.14 (1H, dd, *J* = 3.6, 0.8 Hz), 2.40 (3H, s), 0.99 (21H, s); ¹³C NMR (100 MHz, CDCl₃) δ 183.3, 159.3, 151.2, 141.8, 133.4, 130.0, 128.3, 127.8, 124.2, 121.8, 109.5, 104.2, 96.5, 18.6, 14.2, 11.3; HRMS (ESI, pos): calcd. for C₂₃H₃₁O₂Si [M+H]⁺: 367.2088 found: 367.2088.




Compound 4

To a stirred suspension of (methoxymethyl)triphenylphosphonium chloride (4.71 g, 13.7 mmol, 3.4 Eq) in THF (7.0 mL) was added potassium *tert*-butoxide solution in THF (13.7 mL, 1.0 M in THF, 13.7 mmol, 3.4 Eq) at 0 °C. The mixture was warmed to room temperature and stirred for 2 hours. Compound **3** (1.48 g, 4.04 mmol) in THF (3.0 mL) was subsequently added to the mixture. The mixture was stirred for 10 min at room temperature. Water was added to the mixture and product was extracted to CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and evaporated in a vacuum. The obtained product was purified via flash column chromatography (SiO₂, EtOAc:Hexane 0:100~3:97) to yield compound **4** as a brown oil (1.54 g, 3.91 mmol, 97%, *E/Z* mixture).

Compound **4**: R_f=0.63 (Hexane /EtOAc =9/1); ¹H NMR (400 MHz, CDCl₃)* δ 7.53 (1H ×2, m), 7.35-7.21 (3H ×2, m), 6.82 (1H, s), 6.36 (1H, d, *J*= 3.2 Hz), 6.13 (1H, s), 5.95 (1H, dd, *J*= 3.2, 0.8 Hz), 5.82 (1H, dd, *J*=3.2, 1.2 Hz), 5.45 (1H, d, *J*= 3.2 Hz), 3.80 (3H, s), 3.67 (3H, s), 2.26 (3H, s), 2.19 (3H, s), 1.02 (21H ×2, s); ¹³C NMR (100 MHz, CDCl₃)* δ 151.6, 150.0, 150.8, 149.5, 139.6, 138.2, 134.0, 133.8, 133.2, 133.0, 131.1, 130.8, 128.3, 128.1, 127.4, 127.0, 112.0, 111.0, 109.7, 107.3, 107.1, 106.4, 106.3, 105.9, 93.5, 93.0, 60.8, 60.7, 18.7, 18.7, 13.8, 13.7, 11.6, 11.4; MS (ESI, pos): calcd. for C₂₅H₃₅O₂Si [M+H]⁺: 395.24 found: 395.24.

*Because compound **4** was unstable, several peaks derived from decomposition was observed in ¹H NMR and ¹³C NMR whose intensity increases with longer experiment time.




Compound 5

To a stirred solution of compound **4** (310.2 mg 786.1 μmol) in acetone and water (9:1, 6.0 mL) was added 25 wt% hydrogen bromide-acetic acid solution (294 μL, 1180 μmol, 1.5 Eq). The mixture was gradually heated to 50 °C over 1 hour and stirred for 6 hours. Additional hydrogen bromide-acetic acid solution (100 μL, 401 μmol, 0.51 Eq) was added to the mixture, and the mixture was stirred at 50 °C for 1 hour. After cooled to room temperature, the mixture was quenched with saturated aqueous NaHCO₃ and the product was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered, and evaporated in a vacuum. The obtained aldehyde was unstable thus the next reaction was performed without further purification.

The obtained aldehyde (786.1 μmol) was dissolved in THF and MeOH (1:1, 8.0mL), and NaBH_4 (59.5 mg, 1570 μmol , 2.0 Eq) was added. The mixture was stirred for 10 min at room temperature, and quenched with saturated aqueous NH_4Cl . The product was extracted with CH_2Cl_2 . Organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 0:100~4:96) to obtain compound **5** as brown oil (113.8 mg, 297.4 μmol , 38% for 2 steps).

Compound **5**: R_f =0.61 (Hexane/EtOAc 3/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.53 (1H, d, J = 7.6 Hz), 7.30-7.17 (3H, m), 6.08 (1H, d, J = 3.2 Hz), 5.92 (1H, dd, J =3.2, 0.8 Hz), 4.90 (1H, t, J =2.8 Hz), 4.09 (2H, m), 2.27 (3H, s), 1.65 (1H, t, J =3.2 Hz), 1.15 (21H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) 152.7, 151.6, 141.6, 133.3, 128.8, 127.7, 126.9, 123.5, 108.1, 106.2, 105.1, 95.7, 65.0, 45.8, 18.8, 13.7, 11.5; **HRMS** (ESI, pos): calcd. for $\text{C}_{24}\text{H}_{34}\text{NaO}_2\text{Si}$ $[\text{M}+\text{Na}]^+$: 405.2220 found: 405.2226.




EpOH **6**

EpOH **6**

To a stirred solution of compound **5** (113.8 mg, 297.4 μmol) in THF (8.0 mL) was added 1.0 M solution of tetra-*n*-butylammonium fluoride in THF (327 μL , 327.0 μmol , 1.1 Eq) at 0 $^\circ\text{C}$. The mixture was stirred for 5 min at 0 $^\circ\text{C}$, and subsequently quenched with water. The product was extracted with CH_2Cl_2 . Obtained organic layer was dried over Na_2SO_4 , filtered and evaporated in a vacuum. The product was purified via flash column chromatography (SiO_2 , EtOAc/Hexane 1:9) to yield EpOH **6** as brown oil (58.9 mg, 260.3 μmol , 88%).

Compound **6**: R_f =0.33 (Hexane/EtOAc 3/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) 7.53 (1H, dd, J =7.6, 0.8 Hz), 7.33-7.25 (2H, m), 7.21 (1H, td, J = 7.6, 2.0 Hz), 6.08 (1H, d, J =2.8 Hz), 5.92 (1H, dd, J = 2.8, 0.8 Hz), 4.84 (1H, t, J =6.8 Hz), 4.13-4.00 (2H, m), 3.32 (1H, s), 2.27 (3H, s), 1.74 (1H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 152.6, 151.7, 141.9, 133.3, 129.3, 127.8, 127.0, 122.1, 108.2, 106.3, 81.9, 81.9, 65.1, 45.7, 13.7; **HRMS** (ESI, pos): calcd. for $\text{C}_{15}\text{H}_{14}\text{NaO}_2$ $[\text{M}+\text{Na}]^+$: 249.0886 found: 249.0888.




EpocOSu **7**

EpocOSu **7**

To a stirred solution of compound **6** (24.9 mg, 110 μmol) in CH_3CN (1.5 mL) was added *N,N'*-disuccinimidyl carbonate (84.6 mg, 330 μmol , 3.0 Eq) and triethylamine (46.0 μL , 330 μmol , 3.0 Eq). The mixture was stirred at room temperature for 14 hours, and subsequently quenched with 0.2 M aqueous HCl. The product was extracted to CH_2Cl_2 . The organic layer was dried over Na_2SO_4 , filtered and evaporated in a vacuum. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 2:10~2:5) to yield EpocOSu **7** as a colorless oil (36.4 mg, 99.1 μmol , 90%).

Compound **7**: $R_f=0.37$ (Hexane/EtOAc 1/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.53 (1H, d, $J=7.6$ Hz), 7.33 (1H, td, $J=7.6, 1.2$ Hz), 7.26-7.22 (2H, m), 6.07 (1H, d, $J=3.2$ Hz), 5.91 (1H, dd, $J=3.2, 1.2$ Hz), 5.06 (1H, t, $J=7.2$ Hz), 4.81 (1H, dd, $J=10.4, 7.2$ Hz), 4.71 (1H, dd, $J=10.4, 7.2$ Hz), 3.38 (1H, s), 2.78 (4H, s), 2.26 (3H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 168.5, 152.1, 151.4, 150.3, 140.1, 133.3, 129.4, 127.9, 127.5, 122.1, 108.6, 106.4, 82.6, 81.3, 71.6, 41.9, 25.6, 13.7; **MS** (ESI, pos): calcd. for $\text{C}_{20}\text{H}_{17}\text{NNaO}_6$ $[\text{M}+\text{Na}]^+$: 390.09 found: 390.11.

1.3 Introduction and deprotection Epoc group




8

Compound **8**

To a stirred solution of EpOH **6** (15.9 mg, 70.3 μmol) in CH_2Cl_2 (2.0 mL) was added triethylamine (23.0 μL , 210.8 μmol , 3.0 Eq) and phenyl isocyanate (29.4 μL , 210.8 μmol , 3.0 Eq). The mixture was stirred at room temperature for 1 hour and subsequently quenched with water. The product was extracted with CH_2Cl_2 . The organic layer was dried over Na_2SO_4 , filtered and evaporated in a vacuum. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 0:1~4:96) to yield compound **9** as an amorphous white solid (24.2 mg, 70.1 μmol , 99%).


Compound **8**: $R_f=0.60$ (Hexane/EtOAc 3/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.53 (1H, dd, $J=7.6, 1.2$ Hz), 7.35-7.27 (6H, m), 7.23 (1H, td, $J=7.2, 2.0$ Hz), 7.05 (1H, m), 6.55 (1H, brs), 6.07 (1H, d, $J=2.8$ Hz), 5.90 (1H, dd, $J=2.8, 1.2$ Hz), 5.02 (1H, t, $J=7.6$ Hz), 4.74 (1H, dd, $J=11.2, 7.6$ Hz), 4.54 (1H, dd, $J=11.2, 7.6$ Hz), 3.31 (1H, s), 2.25 (3H, d, $J=1.2$ Hz); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 153.3, 151.7, 151.7, 141.5, 137.9, 133.2, 129.3, 129.2, 127.8, 127.1, 123.6, 122.2, 118.8, 107.9, 106.2, 82.0, 81.7, 66.2, 42.3, 13.7; **HRMS** (ESI, pos): calcd. for $\text{C}_{22}\text{H}_{19}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 368.1257 found: 368.1255.



Compound 9

To a stirred solution of compound **8** (8.1 mg, 23.5 μmol) in CH_2Cl_2 (1.0 mL) was added sodium tetrachloroaurate dihydrate (0.93 mg, 2.35 μmol , 50 mg/mL stock solution in MeOH). The mixture was stirred at room temperature for 5 minutes. The resulting mixture was diluted to CH_2Cl_2 and washed with water. The organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 1:20~1:10) to obtain compound **9** as a white powder (6.7 mg, 19.4 μmol , 83%).

Compound **9**: $R_f=0.31$ (Hexane/EtOAc 3/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.13 (1H, d, $J=7.6$ Hz), 7.59 (1H, d, $J=7.6$ Hz), 7.44-7.27 (6H, m), 7.14-7.04 (3H, m), 6.63 (1H, brs), 5.09 (1H, brs), 4.53 (2H, dd+dd $J=11.2, 6.8$ Hz), 4.26 (1H, t, $J=6.4$ Hz), 2.35 (3H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 153.5, 150.2, 144.1, 143.6, 140.6, 137.8, 129.6, 129.2, 128.0, 126.3, 124.6, 123.7, 122.1, 118.8, 117.2, 67.1, 47.3, 15.4; **HRMS** (ESI, pos): calcd. for $\text{C}_{22}\text{H}_{19}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 368.1257 found: 368.1250.



Compound 11


To a stirred solution of L-Phenylalanine *tert*-butyl ester hydrochloride (11.3 mg, 43.6 μmol) in THF/ H_2O =3/1 (1.2 mL) was added EpocOSu **7** (16.0 mg, 43.6 μmol , 1.0 Eq) and pyridine (14.0 μL , 174.2 μmol , 4.0 Eq). The mixture was stirred at room temperature for 5 hours and subsequently quenched with saturated aqueous ammonium chloride solution. The product was extracted to CH_2Cl_2 and the organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 1:9) to obtain compound **11** as colorless oil (16.7 mg, 35.3 μmol , 81%, dr~1:1).

Compound **11**: $R_f=0.47$ (Hexane/EtOAc=3/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.52 (1H, d, $J=7.2$ Hz), 7.34-7.18 (6H, m), 7.10 (2H, t, $J=7.6$ Hz), 6.04 (1H, d + d, $J=2.8$ Hz), 5.89 (1H, m), 5.13 (1H, d, $J=8.0$ Hz), 4.96 (1H, m), 4.68 (0.5H, dd, $J=10.8, 7.6$ Hz), 4.59-4.44 (2H, m), 4.38 (0.5H, dd, $J=10.8, 7.2$ Hz), 3.31 (0.5H, s), 3.29 (0.5H, s), 3.03 (1H, dd, $J=9.6, 6.0$ Hz), 2.24 (3H, s), 1.37 (9H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 170.6, 155.5, 151.8, 151.6, [141.5, 141.6], 136.2, 133.2,

129.7, 129.7, 129.2, 128.4, 127.8, 127.0, [122.2, 122.2], 107.8, 106.1, 82.4, 81.9, 81.8, 66.0, 55.2, 42.3, 38.6, 28.1, 13.7; **HRMS** (ESI, pos): calcd. for C₂₉H₃₁NaNO₅ [M+Na]⁺: 496.2094 found: 496.2102.

Deprotection of Compound **11**

To a stirred solution of compound **11** (23.7 mg, 50.0 μmol, 1.0 Eq) in CH₂Cl₂ (1.6 mL) was added NaAuCl₄·2H₂O (199 μg in 20 mg/mL stock solution in MeOH, 500 nmol, 0.01 Eq). The mixture was stirred at room temperature for 7 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.4 mL) was added and the mixture was stirred at room temperature for 15 min. The solvent was evaporated. The product was purified via flash column chromatography (SiO₂, EtOAc:Hexane 1:2~3:1) to obtain L-Phenylalanine *tert*-butyl ester as a white powder (9.9 mg, 44.7 μmol, 90%). The ¹H and ¹³C NMR of the product coincided well with the previously reported one.¹



Compound **13**


To a stirred solution of *N*-carbobenzyloxy-L-alanine (14.5 mg, 65.0 μmol) in CH₂Cl₂ (2.0 mL) was added EpOH **6** (17.6 mg, 78.0 μmol, 1.2 Eq), EDC·HCl (24.9 mg, 130 μmol, 2.0 Eq) and DMAP (15.9 mg, 130 μmol, 2.0 Eq). The mixture was stirred at room temperature for 16 h and subsequently quenched with saturated aqueous ammonium chloride solution. The product was extracted to CH₂Cl₂ and the organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, EtOAc:Hexane 1:9) to obtain compound **13** as a colorless oil (26.0 mg, 60.2 μmol, 93%, dr~1/1).

Compound **13**: R_f=0.70 (Hexane/EtOAc=1/1); **¹H NMR** (400 MHz, CDCl₃) δ 7.51 (1H, m), 7.39-7.18 (8H, m), 6.02 (1H, d+d, *J*=3.2 Hz), 5.88 (1H, m), 5.26 (1H, t, *J*=8.8 Hz), 5.09 (2H, s+s), 5.01 (1H, t, *J*=7.2 Hz), 4.73 (0.5H, dd, *J*=11.2, 7.6 Hz), 4.61 (1H, m), 4.47 (0.5H, dd, *J*=10.8, 7.2 Hz), 4.32 (1H, quin, *J*=6.8 Hz), 3.32 (0.5H, s), 3.31 (0.5H, s), 2.24 (3H, s), 1.24 (3H, d+d, *J*=6.8 Hz); **¹³C NMR** (100 MHz, CDCl₃) δ 172.7, 155.6 [151.8, 151.7], [151.3, 151.3], [141.2, 141.0], 136.4, 133.2, 129.3, 128.7, [128.3, 128.2], 127.9, 127.8, [127.2, 127.2], [122.2, 122.1], [108.1, 108.0], 106.2, [82.1, 82.0], 81.7, 67.0, [66.3, 66.3], 49.7, [41.9, 41.8], [18.8, 18.8], 13.7; **HRMS** (ESI, pos): calcd. for C₂₆C₂₅NaNO₅ [M+Na]⁺: 454.1625 found: 454.1628.

Deprotection of Compound **13**

To a stirred solution of compound **13** (21.6 mg, 50.0 μmol, 1.0 Eq) in CH₂Cl₂ (1.6 mL) was added NaAuCl₄·2H₂O (199 μg in 20 mg/mL stock solution in MeOH, 500 nmol, 0.01 Eq). The mixture was stirred at room temperature for 9 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.4 mL) was added and the mixture was stirred at room temperature for 15 min. The solvent was evaporated. The product was purified via flash

column chromatography (SiO₂, CHCl₃:MeOH 1:0~5:1) to obtain *N*-carbobenzyloxy-L-alanine as a white powder (10.9 mg, 48.8 μmol, 98%). The ¹H and ¹³C NMR of the product coincided well with the previously reported one.²



15

Compound **14**


To a stirred solution of EpOH **6** (22.0 mg, 96.8 μmol, 1.2 Eq) in THF (2.0 mL) was added triphosgene (10.3 mg, 34.7 μmol, 0.43 Eq) and pyridine (9.8 μL, 121 μmol, 1.5 Eq) at 0 °C. After the mixture was stirred at room temperature for 1 hour, compound **14** (21.0 mg, 80.7 μmol, 1.0 Eq) was added. The mixture was stirred at room temperature for 3 hours and quenched with saturated aqueous NH₄Cl solution. The product was extracted to CH₂Cl₂, and the organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, Toluene:EtOAc 1:0~50:1) to obtain Compound **15** as a colorless oil (26.7 mg, 52.1 μmol, 65%, dr~1/1).

Compound **15**: R_f=0.58 (Hexane/EtOAc=3/1); ¹H NMR (400 MHz, CDCl₃) δ 7.51, (1H, dd, *J*=8.0, 1.6 Hz), 7.32-7.18 (3H, m), 6.06 (1H, d+d, *J*= 3.2 Hz), 5.88 (1H, m), 5.52 (1H, d, *J*= 4.8 Hz), 5.01 (1H, t, *J*= 7.2 Hz), 4.67 (1H, t+t, *J*= 7.6 Hz), 4.60 (1H, dd, *J*= 8.0, 2.0 Hz), 4.51 (1H, dd+dd *J*= 8.0, 6.4 Hz), 4.31 (1H, dd, *J*= 2.8, 6.0 Hz), 4.25-4.20 (3H, m), 4.03 (1H, m), 3.34 (0.5H, s), 3.33 (0.5H, s), 2.24 (3H, s), 1.51 (1.5H, s), 1.50 (1.5H, s), 1.43 (3H, s), 1.33(3H, s), 1.32 (3H, s); ¹³C NMR (100MHz, CDCl₃) δ 155.0, 151.7, 151.3, 141.0, 133.3, 129.2, 127.9, 127.2, 122.2, 109.7, 108.9, 108.2, 106.2, 96.4, 82.2, 81.6, 70.9, 70.7, 70.6, 68.8, 66.5, [65.7, 65.6], 42.1, 26.2, 26.1, 25.1, 24.6, 13.7: HRMS (ESI, pos): calcd. for C₂₈H₃₂NaO₉ [M+Na]⁺: 535.19 39 found: 535.1944.

Deprotection of Compound **15**

To a stirred solution of compound **15** (15.8 mg, 30.8 μmol, 1.0 Eq) in CH₂Cl₂ (0.8 mL) was added NaAuCl₄·2H₂O (123 μg in 20 mg/mL stock solution in MeOH, 308 nmol, 0.01 Eq). The mixture was stirred at room temperature for 10 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.2 mL) was added and the mixture was stirred at room temperature for 5 min. The solvent was evaporated. The product was purified via flash column chromatography (SiO₂, CHCl₃:MeOH 1:0~5:1) to obtain *N*-Compound **15** as a colorless oil (6.0 mg, 23.1 μmol, 75%). The ¹H and ¹³C NMR of the product coincided well with the previously reported one.³

1.4 Study for orthogonal deprotections




16

Compound 16

To a stirred solution of *N* ϵ -Fmoc-L-lysine methyl ester hydrochloride (50.0 mg, 119.4 μ mol, 1.0 Eq) in CH₂Cl₂ (2.0 mL) was added EpocOSu **7** (70.9 mg, 156.4 μ mol, 1.1 Eq) and pyridine (28.3 μ L, 284.4 μ mol, 2.0 Eq). The mixture was stirred at room temperature for 1.5 hours and quenched with saturated aqueous NH₄Cl solution. The product was extracted to CH₂Cl₂, and the organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, EtOAc:Hexane 1:5~2:5) to obtain compound **16** as a white solid (70.9 mg, 111.7 μ mol, 94%, dr~1/1).

Compound **16**: R_f =0.55 (Hexane/EtOAc =1/1); ¹H NMR (400 MHz, Acetone-*d*₆) δ 7.85 (2H, d, J = 8.0 Hz), 7.68 (2H, d, J = 8.0 Hz), 7.51 (1H, d, J = 6.4 Hz), 7.43-7.23 (7H, m), 6.57 (1H, brd, J =8.0 Hz), 6.50 (1H, m), 6.11 (1H, m), 5.95 (1H, m), 4.94 (1H, t, J = 6.8 Hz), 4.63 (0.5H, dd, J = 10.8, 6.8 Hz), 4.56 (0.5 H, dd, J = 11.8, 8.0 Hz), 4.44-4.14 (5H, m), 3.93 (0.5H, s), 3.92 (0.5H, s), 3.65 (3H, s), 3.14 (2H, m), 2.18 (3H, s), 1.87-1.20 (6H, m); ¹³C NMR (100 MHz, Acetone-*d*₆) 173.6, 157.2, 156.8, 153.0, 151.9, 145.2, [142.4, 142.4], 142.1, 133.7, 129.9, 128.7, 128.5, 127.9, 126.1, 123.1, 123.1, 120.8, 108.5, 107.0, 83.9, 82.2, 66.7, 66.0, 54.9, 52.2, 48.1, 43.2, 41.1, 32.0, 23.6, 13.4; HRMS (ESI, pos): calcd. for C₃₈H₃₈NaN₂O₇ [M+Na]⁺: 657.2571 found: 657.2577.



17


Compound 17

To a stirred solution of compound **16** (31.7 mg, 50.0 μ mol) in CH₂Cl₂ (1.6 mL) was added piperidine (0.4 mL). The mixture was stirred at room temperature for 1 hour. The product was triturated in hexane, filtered and diluted to CH₂Cl₂. The solution was washed with saturated NaHCO₃, dried over Na₂SO₄, filtered and evaporated. After azeotroped with toluene, compound **17** was obtained as white solid (17.8 mg, 43.2 μ mol, 86%, dr~1/1).

Compound **17**: R_f =0.10 (CHCl₃/MeOH =4/1); ¹H NMR (400 MHz, CD₃OD) δ 7.48 (1H, d, J =7.6 Hz), 7.34-7.19 (3H, m), 6.05 (1H, m), 5.91 (1H, m), 4.96 (1H, m), 4.64 (0.5H, dd, J = 10.8,

7.6 Hz), 4.54 (0.5H, dd, $J=11.2, 7.6$ Hz), 4.60 (0.5H, dd, $J=10.8, 7.2$ Hz), 4.38 (1H, dd, $J=11.2, 7.2$ Hz), 4.11 (1H, dt, $J=9.6, 4.0$ Hz), 3.76* (0.5H, s), 3.75* (0.5H, s), 3.69 (3H, s), 2.61 (2H, m), 2.21 (3H, s), 1.75 (1H, m), 1.64 (1H, m), 1.50-1.39 (2H, m), 1.28-1.31 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ [174.6, 174.6], 158.4, 153.2, 152.5, 142.6, 134.0, 130.0, 128.8, 128.0, 123.6, 108.7, 107.1, 83.5, 82.4*, 66.8, 55.4, 52.6, 43.6, 42.1, 33.0, 32.3, 24.1, 13.4; **HRMS** (ESI, pos): calcd. for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$: 413.2071 found: 413.2069.

* Because the proton at terminal alkyne was substituted to deuterium in CD_3OD , its signal become lower than expected in $^1\text{H NMR}$. In addition, the signal derived from deuterated product was also observed in $^{13}\text{C NMR}$.




18

Compound **18**

To a stirred solution of *N* ϵ -Boc-L-lysine methyl ester hydrochloride (52.1 mg, 142.2 μmol , 1.0 Eq) in CH_2Cl_2 (2.0 mL) was added EpocOSu **7** (48.2 mg, 131.3 μmol , 1.1 Eq) and pyridine (19.2 μL , 238.7 μmol , 2.0 Eq). The mixture was stirred at room temperature for 1.5 hours and quenched with saturated aqueous NH_4Cl solution. The product was extracted to CH_2Cl_2 , and the organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 1:5~2:5) to obtain compound **18** as a white solid (69.2 mg, 135.0 μmol , 77%, dr~1/1).

Compound **18**: $R_f=0.69$ (Hexane/EtOAc=1/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.51 (1H, d, $J=7.6$ Hz), 7.32-7.17 (3H, m), 6.04 (0.5H, d, $J=2.8$ Hz), 6.03 (0.5H, d, $J=3.2$ Hz), 5.88 (1H, m), 5.18 (1H, brd, $J=8.0$ Hz), 4.95 (1H, t, $J=6.4$ Hz), 4.68-4.40 (3H, m), 4.30 (1H, m), 3.72 (3H, s), 3.32 (1H, s), 3.07 (2H, m), 2.23 (3H, s), 1.79 (1H, m), 1.62 (1H, m), 1.51-1.42 (11H, m), 1.36-1.23 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 173.0, 156.1, 155.8, [151.8, 151.8] 151.6, 141.5, 133.2, 129.2, 127.8, 127.0, 122.2, 107.8, 106.1, 81.9, 81.8, 79.3, [66.1, 66.0], 53.7, 52.5, 42.3, 40.3, 32.4, 29.6, 28.5, 22.4, 13.7; **HRMS** (ESI, pos): calcd. for $\text{C}_{28}\text{H}_{36}\text{NaN}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$: 535.2415 found: 535.2425.




19

Compound 19 (Epoc deprotection of compound 18)

To a stirred solution of compound **18** (25.6 mg, 50.0 μmol , 1.0 Eq) in CH_2Cl_2 (1.6 mL) was added $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ (199 μg in 20 mg/mL stock solution in MeOH, 500 nmol, 0.01 Eq). The mixture was stirred at room temperature for 10 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.4 mL) was added and the mixture was stirred at room temperature for 30 min. The solvent was evaporated. The product was purified via flash column chromatography (SiO_2 , CHCl_3 :MeOH 1:0~9:1) to obtain *N* ϵ -Boc-L-lysine methyl ester as a white powder (11.8 mg, 45.3 μmol , 91%). The ^1H and ^{13}C NMR of the product coincided well with the previously reported one.⁴

Boc deprotection of compound 18

To a stirred solution of compound **18** (25.6 mg, 50.0 μmol , 1.0 Eq) in CH_2Cl_2 (0.9 mL) was added trifluoroacetic acid (0.1 mL) at 0 $^\circ\text{C}$. The mixture was stirred at 0 $^\circ\text{C}$ for 3 hours and quenched with saturated aqueous NaHCO_3 solution. The product was extracted to CH_2Cl_2 . The organic layer was dried over Na_2SO_4 , filtered and evaporated to obtain compound **17** as a white powder (17.8 mg, 43.2 μmol , 86%). The ^1H NMR and ^{13}C NMR peaks of the obtained product coincided well with the product obtained in the Fmoc deprotection of compound **16**.




20

Compound 20 (Me deprotection of compound 18)

To a stirred solution of compound **18** (25.6 mg, 50.0 μmol , 1.0 Eq) in THF/ H_2O =3/1 (2.0 mL) was added $\text{LiOH} \cdot \text{H}_2\text{O}$ (6.4 mg, 150 μmol , 3.0 Eq). The mixture was stirred at room temperature for 1 hour and quenched with 0,1 M aqueous HCl. The product was extracted to CH_2Cl_2 . The organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via silica gel column chromatography (SiO_2 , CHCl_3 :MeOH 1:0 ~ 9:1) to obtain compound **20** as a white powder (19.3 mg, 38.7 μmol , 77%, dr ~1/1).

Compound **20**: $R_f=0.42$ ($\text{CHCl}_3/\text{MeOH}=4/1$) ; $^1\text{H NMR}$ (400 MHz, CD_3OD) δ 7.48 (1H, d, $J=8.0$ Hz), 7.32-7.21 (3H, m), 6.06 (1H, m), 5.91 (1H, m), 4.97 (1H, t+t, $J=7.6$ Hz), 4.65 (0.5 H, dd, $J=10.4, 7.2$ Hz), 4.51 (1H, m), 4.37 (0.5H, dd, $J=10.8, 7.2$ Hz), 4.07 (1H, m), 3.75 (0.5H, s), 3.75 (0.5H, s), 3.02 (2H, m), 2.21 (3H, s), 1.78 (1H, m), 1.60 (1H, m), 1.54-1.24 (13H, m); $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 175.9, 158.5, 158.4, 153.2, 152.5, [142.7, 142.6], 134.0, 130.4, 128.9, 128.0, 123.6, 108.8, 107.1, 82.4, 82.4, 79.9, 66.8, 55.2, 43.6, 41.1. 32.4, 30.4, 28.8, 24.1, 13.4; **HRMS** (ESI, pos): calcd. for $\text{C}_{27}\text{H}_{34}\text{NaN}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$: 521.2258 found: 521.2263.




S1

Compound **S1**

To a stirred solution of *N* α -Fmoc-*N* ϵ -Alloc-lysine (100.0 mg, 221.0 μmol , 1.0 Eq) in DMF (5.0 mL) was added MeI (27.5 μL , 442.0 μmol , 2.0 Eq) and K_2CO_3 (61.1 mg, 442.0 μmol , 2.0 Eq). The mixture was stirred at room temperature for 2 hours and quenched with 0.2 M aqueous HCl solution. the product was extracted to CH_2Cl_2 . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and evaporated. The product was purified via Silica gel column chromatography (SiO_2 , Hexane: EtOAc 4:1~2.5:1) to obtain compound **S1** (103.4 mg, 221.0 μmol , 100%) as a white powder.

Compound **S1**: $R_f=0.72$ ($\text{CHCl}_3/\text{MeOH}=9/1$); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.76 (2H, d, $J=7.6$ Hz), 7.60 (2H, m), 7.40 (2H, t, $J=7.6$ Hz), 7.32 (2H, t, $J=7.6$ Hz), 5.90 (1H, m), 5.37 (1H, d, $J=7.6$ Hz), 5.28 (1H, d, $J=17.2$ Hz), 5.18 (1H, d, $J=10.4$ Hz), 4.76 (1H, m), 4.55 (2H, m), 4.40 (3H, m), 4.22 (1H, t, $J=6.8$ Hz), 3.75 (3H, s), 3.19 (2H, brq, $J=6.4$ Hz), 1.84 (1H, m), 1.69 (1H, m), 1.53 (2H, m), 1.39 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 173.0, 156.5, 156.1, 143.9, 141.5, 133.1, 127.9, 127.2, 125.2, 120.1, 117.8, 67.2, 66.7, 53.8, 52.6, 47.3, 40.6, 32.3, 29.5, 22.4; **HRMS** (ESI, pos): calcd. for $\text{C}_{26}\text{H}_{30}\text{NaN}_2\text{O}_6$ $[\text{M}+\text{Na}]^+$: 489.1996 found: 489.1999.




22

Compound **22**

To a stirred solution of compound **S1** (103.4 mg, 221.0 μmol , 1.0 Eq) in CH_2Cl_2 (1.6 mL) was added piperidine (0.4 mL). The mixture was stirred at room temperature for 30 minutes and evaporated. The product was purified via Silica gel column chromatography (SiO_2 , CHCl_3 :MeOH 1:0~50:1) to obtain compound **22** (51.4 mg, 210.4 μmol , 95%) as white powder.

Compound **22**: $R_f=0.20$ (CHCl_3 /MeOH =9/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.91 (1H, ddd, $J=16.8, 10.8, 5.6$ Hz), 5.29 (1H, dq, $J= 16.8, 1.6$ Hz), 5.20 (1H, dq, $J= 10.8, 1.6$ Hz), 4.75 (1H, m), 4.55 (2H, d, $J= 5.6$ Hz), 3.72 (3H, s), 3.43 (1H, dd, $J= 8.0, 5.6$ Hz), 3.18 (2H, q, $J= 6.8$ Hz), 1.74 (1H, m), 1.61-1.45 (3H, m), 1.44-1.37 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 176.6, 156.4, 133.1, 117.7, 66.6, 54.4, 52.1, 40.9, 34.6, 29.8, 23.0; **HRMS** (ESI, pos): calcd. for $\text{C}_{11}\text{H}_{21}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 245.1496 found: 245.1497.



21

Compound **21**


To a stirred solution of compound **22** (37.1 mg, 101.0 μmol , 1.0 Eq) in CH_2Cl_2 (2.0 mL) was added EpocOSu **7** (27.1 mg, 111.1 μmol , 1.1 Eq) and pyridine (16.3 μL , 202.0 μmol , 2.0 Eq). The mixture was stirred at room temperature for 2 hours and quenched with saturated aqueous NH_4Cl solution. The product was extracted to CH_2Cl_2 , and the organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , EtOAc:Hexane 1:5~2:5) to obtain compound **21** as a colorless oil (37.6 mg, 75.7 μmol , 75%, dr~1/1).

Compound **21**: $R_f=0.55$ (Hexane/EtOAc= 1/1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.51 (1H, d, $J= 7.6$ Hz), 7.30-7.19 (3H, m), 6.03 (1H, m), 5.96-5.87 (2H, m), 5.29 (1H, d, $J=17.6$ Hz), 5.20 (2H, m), 4.96 (1H, t, $J= 6.8$ Hz), 4.77-4.41 (5H, m), 4.30 (1H, m), 3.72 (3H, s), 3.32 (1H, s), 3.16 (1H, m), 2.24 (3H, s), 1.80 (1H, m), 1.62 (1H, m), 1.55-1.43 (2H, m), 1.36-1.22 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.9, 156.4, 155.8, 151.8, 151.6, 141.5, 133.2, 122.1, 129.2, 127.8, 127.0, 122.2, 117.8, 107.8, 106.1, 81.9, 81.8, 66.2, 65.6, 53.7, 52.5, 42.3, 40.7, 32.4, 29.5, 22.3, 13.7; **HRMS** (ESI, pos): calcd. for $\text{C}_{27}\text{H}_{32}\text{NaN}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$: 519.2102 found: 519.2108.

Epoc deprotection of compound **21**

To a stirred solution of compound **21** (22.3 mg, 44.9 μmol , 1.0 Eq) in CH_2Cl_2 (1.6 mL) was added $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ (179 μg in 20 mg/mL stock solution in MeOH, 449 nmol, 0.01 Eq). The mixture was stirred at room temperature for 10 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.4 mL) was added and the mixture was stirred at room temperature for 30 min. The solvent was evaporated. The product was purified via flash column chromatography (SiO_2 , CHCl_3 :MeOH 1:0~50:1) to obtain compound **22** as a white powder (11.8 mg, 45.3 μmol , 91%). The NMR spectra of this product coincided well with the one shown above for compound **22**.


Alloc deprotection of compound **21** (Compound **17'**)



To a stirred solution of compound **22** (24.9 mg, 50.1 μmol , 1.0 Eq) and dimedone (35.2 mg, 250.5 μmol , 5.0 Eq) in THF (2.0 mL) was added Pd(PPh₃)₄ (2.9 mg, 2.51 μmol , 0.05 Eq). The mixture was stirred at room temperature for 20 minutes and diluted to Et₂O. The product was extracted to 1M aqueous HCl solution and the solution was then poured into saturated aqueous NaHCO₃ solution slowly. The product was then extracted to CH₂Cl₂ and the organic layer was dried over Na₂SO₄, filtered and evaporated. To a solution of the product in Et₂O was added 1M HCl solution in Et₂O to crystallize the product as HCl salt. The product was filtered with celite, diluted to MeOH, and evaporated to obtain compound **17'** as HCl salt (16.6 mg, 37.0 μmol , 74%, dr~1/1).

Compound **17'**: R_f = 0.10 (CHCl₃/MeOH = 4/1); ¹H NMR (400 MHz, CD₃OD) δ 7.48 (1H, d, *J* = 8.0 Hz), 7.35-7.20 (3H, m), 6.05 (1H, m), 5.92 (1H, m), 4.96 (1H, t, *J* = 7.2 Hz), 4.64-4.54 (1H, m), 4.46-4.38 (1H, m), 4.14 (1H, quin *J* = 4.0 Hz), 3.77* (0.5H, s), 3.76* (0.5H, s), 3.70 (3H, s), 2.90 (2H, t, *J* = 7.6 Hz), 2.21 (3H, s), 1.88-1.58 (4H, m), 1.50-1.32 (2H, m); ¹³C NMR (100 MHz, CD₃OD) δ 174.2, 158.4, 153.1, 152.6, 142.6, 134.0, 130.1, 128.8, 128.1, 123.6, 108.8, 107.1, 83.5, 82.4, 66.8, 55.0, 52.7, 43.6, 40.5, 32.0, 28.0, 23.8, 13.4; HRMS (ESI, pos): calcd. for C₂₃H₂₉N₂O₅ [M-Cl]⁺: 413.2071 found: 413.2071.


Compound **S2**



To a stirred solution of *N* α -Fmoc-*N* ϵ -Dde-lysine (110.4 mg, 207.3 μmol , 1.0 Eq) in THF (2.0 mL) was added benzylamine (90.6 μL , 829 μmol , 4.0 Eq), EDC·HCl (79.5 mg, 415 μmol , 2.0 Eq), HOBT (56.0 mg, 415 μmol , 2.0 Eq), and *N*-methyl-morpholine (91.2 μL , 829 μmol , 4.0 Eq). The mixture was stirred at room temperature for 4 hours and quenched with 1M aqueous HCl. The product was extracted to CH₂Cl₂ and the organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, CHCl₃:MeOH 1:0~50:1) to obtain compound **S2** as a white powder (116.0 mg, 186.6 μmol , 90%).

Compound **S2**: $R_f=0.57$ ($\text{CHCl}_3/\text{MeOH}=9/1$); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.75 (2H, d, $J=7.6$ Hz), 7.57 (2H, d, $J=7.6$ Hz), 7.39 (2H, t, $J=7.6$ Hz), 7.32-7.20 (3H, m), 6.62 (1H, m), 5.52 (1H, d, $J=8.0$ Hz), 4.45-4.37 (4H, m), 4.17 (2H, t, $J=6.8$ Hz), 3.19 (2H, t, $J=6.8$ Hz), 3.36 (2H, m), 2.53 (3H, s), 2.29 (4H, s), 1.93 (1H, m), 1.77-1.63 (3H, m), 1.55-1.41 (2H, m), 0.99 (6H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 197.1, 196.8, 173.7, 171.4, 156.4, 143.9, 141.5, 137.9, 128.9, 127.9, 127.8, 127.8, 127.2, 125.2, 120.2, 108.0, 67.2, 54.8, 53.6, 52.4, 47.3, 43.8, 43.2, 32.3, 30.2, 28.4, 28.3, 23.0, 18.1; **HRMS** (ESI, pos): calcd. for $\text{C}_{38}\text{H}_{44}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 622.3275 found: 622.3280.

Compound **24**




24

To a stirred solution of compound **S2** (103.4 mg, 221.0 μmol , 1.0 Eq) in CH_2Cl_2 (1.6 mL) was added piperidine (0.4 mL). The mixture was stirred at room temperature for 20 minutes and evaporated. The product was purified via Silica gel column chromatography (SiO_2 , $\text{CHCl}_3:\text{MeOH}$ 1:0~20:1) to obtain compound **24** (46.4 mg, 116.1 μmol , 80%) as white powder.

Compound **24**: $R_f=0.29$ ($\text{CHCl}_3/\text{MeOH}=9/1$); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.65 (1H, t, $J=6.0$ Hz), 7.35-7.26 (4H, m), 4.45 (2H, d, $J=6.0$ Hz), 3.44-3.36 (3H, m), 2.55 (3H, s), 2.35 (4H, s), 1.99-1.90 (1H, m), 1.79-1.43 (5H, m), 1.03 (6H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 199.2, 196.9, 174.7, 173.6, 138.5, 128.8, 127.9, 127.5, 108.0, 55.0, 53.5, 52.4, 43.2, 34.7, 30.2, 29.8, 28.8, 28.4, 23.2, 18.1, ; **HRMS** (ESI, pos): calcd. for $\text{C}_{23}\text{H}_{34}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 400.2595 found: 400.2600.

Compound **23**




23

To a stirred solution of Compound **24** (46.4 mg, 116 μmol , 1.0 Eq) in THF (2.0 mL) was added EpocOSu **7** (55.5 mg, 151 μmol , 1.3 Eq) and Et_3N (35.9 μL , 348 μmol , 3.0 Eq). The mixture was stirred at room temperature for 1 hour and quenched with 1.0M aqueous HCl solution. The product was extracted to CH_2Cl_2 , and the organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , $\text{CHCl}_3:\text{MeOH}$ 1:0~50:1) to obtain compound **23** as a white solid (71.4 mg, 109.5 μmol , 94%, dr~1/1).

Compound **23**: $R_f=0.53$ ($\text{CHCl}_3/\text{MeOH}=9/1$); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.48 (1H, d, $J=7.6$ Hz), 7.34-7.15 (8H, m), 6.59 (1H, m), 6.00 (1H, m), 5.85 (1H, m), 5.27 (1H, m), 4.94 (1H, t, $J=6.8$ Hz), 4.61 (1H, m), 4.47-4.39 (3H, m), 4.13 (1H, m), 3.38-3.25 (3H, m), 2.53 (3H, s), 2.31 (4H, s), 2.22 (3H, s), 1.94-1.83 (1H, m), 1.74-1.44 (3H, m), 1.49-1.35 (2H, m), 1.00 (6H, s); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 199.1, 196.9, 173.7, 171.3, 156.2, 151.6, 151.6 [141.5, 141.4] 138.0, 133.2, 129.2, 128.9, 127.8, 127.8, 127.7 127.1, [122.2, 122.2], 108.0, 107.9, 107.8, 106.2, 82.0, 81.8, [66.3, 66.2], 54.7, 53.4, 52.4, 43.7, 43.2, 42.3, 32.2, 32.1, 30.2, 28.4, 23.0, 18.1, 13.7; **MS** (ESI, pos): calcd. for $\text{C}_{39}\text{H}_{46}\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 652.3381 found: 652.3380.

Compound **25**



25


To a stirred solution of compound **23** (32.6 mg, 50.0 μmol , 1.0 Eq) in MeOH (1960 μL) was added hydrazine monohydrate (40 μL). The mixture was stirred at room temperature for 1 hour and triturated in Hexane/ $\text{Et}_2\text{O}=1/1$. The precipitate was filtered with Celite and dissolved in MeOH, and evaporated. To a solution of the product in $\text{Et}_2\text{O}/\text{MeOH}=9/1$ was added 1M HCl solution in Et_2O to crystallize the product as HCl salt. The product was filtered with celite, dissolved in MeOH, and evaporated to obtain compound **25** as a white powder (18.8 mg, 35.9 μmol , 72%, $\text{dr}\sim 1/1$).

Compound **25**: $R_f=0.10$ ($\text{CHCl}_3/\text{MeOH}=4/1$); $^1\text{H NMR}$ (400 MHz, CD_3OD) δ 7.47 (1H, m), 7.35-7.19 (8H, m), 6.04 (1H, d, $J=2.8$ Hz), 5.90 (1H, m), 4.96 (1H, m), 4.65 (0.5H, dd, $J=10.8, 7.6$ Hz), 4.57 (0.5H, dd, $J=10.8, 7.6$ Hz), 4.49-4.29 (3H, m), 4.07 (1H, m), 3.74 (1H, s $\times 2$), 2.87 (2H, m), 2.20 (3H, s $\times 2$), 1.78 (1H, m), 1.70-1.55 (3H, m), 1.47-1.30 (2H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.5, 158.2, 153.1, 152.6, [142.6, 142.5], 139.8, 134.0, 130.1, 129.5, 128.8, [128.5, 128.5], 128.2, 128.1, 123.6, 108.8, 107.1, 83.5, [82.4, 82.4], 66.9, 56.3, 44.0, 43.5, 40.5, 32.6, 28.0, 23.8, 13.4; **MS** (ESI, pos): calcd. for $\text{C}_{29}\text{H}_{34}\text{N}_3\text{O}_4$ $[\text{M}-\text{Cl}]^+$: 488.2544 found: 488.2541.

Epoc deprotection of compound **24**

To a stirred solution of compound **24** (32.6 mg, 50.0 μmol , 1.0 Eq) in CH_2Cl_2 (1.6 mL) was added $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ (199 μg in 20 mg/mL stock solution in MeOH, 500 nmol, 0.01 Eq). The mixture was stirred at room temperature for 30 min. After the completion of the transformation of Epoc group was confirmed by TLC, piperidine (0.4 mL) was added and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated. The product was purified via flash column chromatography (SiO_2 , $\text{CHCl}_3:\text{MeOH}$ 1:0~20:1) to obtain compound **23** as a white powder (18.0 mg, 45.0 μmol , 90%). The NMR spectra of this product coincided well with the one shown above for compound **24**.

1.5 Synthesis of Epoc-protected amino acids for solid-phase peptide synthesis




Epoc-Val-OH

Epoc-Val-OH

To a stirred solution of EpocOSu **7** (40.1 mg, 109.2 μmol , 1.0 Eq) and L-Valine (14.1 mg, 120.1 μmol , 1.1 Eq) in THF/H₂O =3/1 (2.0 mL) was added Et₃N (33.8 μL , 328 μmol , 3.0 Eq). The mixture was stirred at room temperature for 30 minutes and quenched with 0.2 M aqueous HCl solution. The product was extracted to CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, CHCl₃:MeOH 1:0~20:1) to obtain Epoc-Val-OH (38.0 mg, 102.9 μmol , 94%, dr~1/1) as a colorless oil.

Epoc-Val-OH: R_f=0.60 (CHCl₃/MeOH =4/1); ¹H NMR (400 MHz, CDCl₃) δ 7.50 (1H, d, *J*=8.0 Hz), 7.32-7.15 (3H, m), 6.05 (1H, m), 5.88 (1H, m), 5.10 (1H, d, *J*=9.2 Hz), 4.97 (1H, t, *J*=7.2 Hz), 4.69 (0.5H, dd, *J*=10.8, 8.0 Hz), 4.61(0.5H, dd, *J*=10.8, 8.0 Hz), 4.51 (0.5H, dd, *J*=10.8, 7.2 Hz), 4.43 (0.5H, dd, *J*=10.8, 7.2 Hz), 4.27 (1H, m), 3.31 (1H, s), 2.23(3H, s), 2.22-2.12 (1H, m), 1.00-0.80 (6H, m); ¹³C NMR (100 MHz, CDCl₃) δ 176.3, 156.3, 151.8, 151.6, 141.4, 133.2, 129.2, 127.8, 127.1, 122.2, 107.9, 106.1, [82.0, 81.9], 81.7, 66.2, 58.9, [42.4, 42.1], 31.2, 19.1, 17.5, 13.7; HRMS (ESI, pos): calcd. for C₂₁H₂₃NaNO₅ [M+Na]⁺: 392.1468 found: 392.1464.

Fmoc-Lys(Epoc)-OH




Fmoc-Lys(Epoc)-OH

To a stirred solution of EpocOSu **7** (45.1 mg, 123 μmol , 1.0 Eq) and *N* α -Fmoc-lysine hydrochloride (54.7 mg, 135 μmol , 1.1 Eq) in THF/H₂O =3/1 (4.0 mL) was added Et₃N (50.6 μL , 491 μmol , 4.0 Eq). The mixture was stirred at room temperature for 30 minutes and quenched with 1.0 M aqueous HCl solution. The product was extracted to CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and evaporated. The product was purified via flash column chromatography (SiO₂, CHCl₃:MeOH 50:1~7:1) to obtain Fmoc-Lys(Epoc)-OH (65.4 mg, 105.4 μmol , 86%, dr~1/1) as white powder.

Fmoc-Lys(Epoc)-OH: R_f=0.58 (CHCl₃/MeOH =4/1); ¹H NMR (400 MHz, CD₃OD) δ 7.77 (2H, d, *J*=7.6 Hz), 7.65 (2H, t, *J*=6.4 Hz), 7.44 (1H, d, *J*=7.6 Hz), 7.37 (2H, t, *J*=7.6 Hz), 7.32-7.23

(4H, m), 7.18 (1H, d, $J=7.2$ Hz), 6.01 (1H, m), 5.87 (1H, m), 4.92 (1H, t, $J=6.4$ Hz), 4.56 (1H, m), 4.45-4.29 (3H, m), 4.20 (1H, m), 4.11 (1H, m), 3.72 (1H, s), 3.04 (2H, t, $J=6.4$ Hz), 2.17 (3H, s), 1.87-1.76 (1H, m), 1.75-1.60 (1H, m), 1.51-1.30 (4H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 176.1, 158.7, 158.7, 153.3, 152.5, [145.3, 145.2], 142.7, 142.6, 134.0, 130.0, 128.8, 128.2, 128.2, 128.0, 126.3, 123.6, 120.9, 108.7, 107.0, 83.4, 82.5, 67.9, 66.6, 56.3, 48.4, 43.6, 41.3, 32.3, 30.3, 24.1, 13.4; **HRMS** (ESI, pos): calcd. for $\text{C}_{37}\text{H}_{36}\text{NaN}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$: 643.2415 found: 643.2419.



Epoc-Lys(Fmoc)-OH

Epoc-Lys(Fmoc)-OH

To a stirred solution of EpocOSu **7** (109.6 mg, 298.4 μmol , 1.0 Eq) and $N\epsilon$ -Fmoc-lysine (164.9 mg, 447.5 μmol , 1.5 Eq) in $\text{THF}/\text{H}_2\text{O}=5/3$ (6.0 mL) was added Et_3N (166.3 μL , 1.190 mmol, 4.0 Eq). The mixture was stirred at room temperature for 30 minutes and quenched with 1.0 M aqueous HCl solution. The product was extracted to CH_2Cl_2 . The organic layer was dried over Na_2SO_4 , filtered and evaporated. The product was purified via flash column chromatography (SiO_2 , CHCl_3 :MeOH 1:0~20:1) to obtain Epoc-Lys(Fmoc)-OH (155.3 mg, 250.2 μmol , 84%, dr~1/1) as white powder.

Epoc-Lys(Fmoc)-OH: $R_f=0.44$ ($\text{CHCl}_3/\text{MeOH}=4/1$); $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 7.88 (2H, d, $J=7.2$ Hz), 7.68 (2H, d, $J=7.2$ Hz), 7.49 (1H, d, $J=7.6$ Hz), 7.43-7.20 (7H, m), 6.12 (1H, m), 5.98 (1H, m), 4.82 (1H, q, $J=6.4$ Hz), 4.56-4.19 (6H, m), 3.81 (1H, m), 2.94 (2H, m), 2.17 (3H, s), 1.71-1.04 (6H, m); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.1, 156.1, 155.8, 151.8, 150.7, 144.0, [141.1, 141.0], 140.8, 132.7, 129.2, 127.6, 127.2, 127.1, 125.2, 121.7, 121.6, 120.1, [107.6, 107.55], 106.4, 81.3, 79.2, 65.2, 64.7, 54.1, 46.8, 41.8, 41.3, 30.7, 29.0, 22.8, 13.3; **HRMS** (ESI, pos): calcd. for $\text{C}_{37}\text{H}_{36}\text{NaN}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$: 643.2415 found: 643.2419.

2. Solvent screening for the fluorene formation of Epoc group

2.1 HPLC product standard curves and calibration

The calibration curve for the integrated value of compound **9** was constructed using the standard solution in 1,4-dioxane to determine the yield for compound **9** from HPLC analysis (**Figure S1, S2**). For HPLC analysis, analytical 4.6 \times 250 mm Cosmosil 5C₁₈-AR-300 column from Nacalai Tesque (Kyoto, Japan) was used with 1.0 mL/min flow rate. The elution method was shown in **Table S1**.




Figure S1 Calibration curve for compound **9**




Figure S2 HPLC chart of compound **9** with different injected amount.

Table S1 HPLC method

Time (min)	Flow rate (mL/min)	H ₂ O with 0.1% TFA (%)	CH ₃ CN with 0.1% TFA (%)
0	1.0	45	55
5	1.0	45	55
30	1.0	25	75

2.2 Condition screening for fluorene formation

Compound **8** (300 nmol) from the stock solution in 1,4-dioxane (20 mg/mL, 5.2 μ L) was diluted to the various solvents (192.4 μ L). The stock solution of NaAuCl₄·2H₂O (3 nmol or 30 nmol) in MeOH (2.4 μ L, 5 mg/mL or 0.5 mg/mL) was added to the solution of compound **8** and the total volume of the reaction solution was adjusted to 200 μ L. The mixture was placed at room temperature for 1 hour and quenched with 1-dodecanethiol (50 Eq). The mixture was diluted in 5 times in volume with 1,4-dioxane, and 20 μ L of this solution was injected to HPLC analysis (condition: **Table S1**, chart **Figure S3**). The yield was determined based on the calibration curve obtained above. The experiments were run in triplicate and its average was shown as the yield.






Figure S3 HPLC chart for solvent screening of fluorene formation


(d) 10 mol% [Au] in 1,4-dioxane



(e) 1 mol% [Au] in 1,4-dioxane



(f) 10 mol% [Au] in THF



(g) 10 mol% [Au] in Acetone




Figure S3 HPLC chart for solvent screening of fluorene formation (continued).






Figure S3 HPLC chart for solvent screening of fluorene formation (continued).

2.3 Fluorene formation under aqueous conditions

To a solution of $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ in PBS buffer (90 μL) and 1,4-dioxane (4.82 μL) was added compound **8** (300 nmol) from the stock solution in 1,4-dioxane (20 mg/mL, 5.18 μL). The mixture was placed at 37 $^\circ\text{C}$ for 24 hours, and quenched with 1-dodecanethiol (50 Eq). The mixture was diluted 10 times in volume with 1,4-dioxane, and 20 μL of this solution was injected to HPLC analysis (condition: **Table S1**, chart **Figure S4**). The yield was determined based on the calibration curve obtained above. The experiments were run in triplicate and its average was shown as the yield.




Figure S4 HPLC chart for fluorene formation under aqueous conditions.

3. Solid-phase peptide synthesis

3.1 Test for Epoc transformation on resin

2-Chlorotriyl chloride resin (1.57 mmol/g, 100-200 mesh, 1% DVB) was treated with Fmoc-Phe-OH (2.0 Eq), DIPEA (5.0 Eq) in CH_2Cl_2 for 2 hours. After washing with $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{DIPEA} = 17/2/1$ (2 mL \times 3), CH_2Cl_2 (2 mL \times 3), and DMF (2 mL \times 3), 20%

piperidine/DMF was added to the resin and the resin was shaken for 10 min, and washed with DMF (0.5 mL, 5 times). The amount of active N-terminal was determined by the quantification of cleaved dibenzofulvene-piperidine adduct. The coupling with Epoc-Val-OH was performed by the treatment with Epoc-Val-OH (4.0 Eq), HOBt (4.0 Eq), HBTU (4.0 Eq), and DIPEA (8.0 Eq) in DMF (500 μ L) for 15 min to obtain the resin loaded with Epoc-Val-Phe-OH. After the coupling, the resins were washed with CH₂Cl₂ (1 mL, 3 times) and DMF (1 mL, 3 times).


The transformation of Epoc group was performed with the treatment of NaAuCl₄·2H₂O (0.1 Eq, 20 mg/mL stock solution in MeOH) and CH₂Cl₂ (500 μ L) for 10 min. After the treatment, the resins were washed with CH₂Cl₂ (1 mL, 3 times) and DMF (1 mL, 3 times). The transformed Hmoc group was removed by the treatment of 20% piperidine/DMF for 10 min twice. The elongation was performed by the treatment with Fmoc-Gly-OH (4.0 Eq), HOBt (4.0 Eq), and DIPEA (8.0 Eq) in DMF (500 μ L) for 15 min. The peptide cleaved with 1% TFA in CH₂Cl₂ showed a single major peak in HPLC analysis. The mass spectra of the peptide obtained from this fraction showed the peak derived from desired Fmoc-Gly-Val-Phe-OH **29** (HRMS (ESI, pos): calcd. for C₃₀H₃₂N₂NaO₆ [M+Na]⁺: 539.2153 found: 539.2159). The reaction procedure of each step was monitored with the HPLC analysis of the peptide cleaved from the small portion of resin (condition: **Table S2**, chart: **Figure S5**). In this step, we used the cleavage cocktail containing thiol reagent (TFA/1-dodecanethiol/ CH₂Cl₂ =2/8/90) to quench residual gold(III) catalysts absorbed on resin and avoid the transformation after cleavage.

As a negative control, 20% piperidine/DMF was treated to Epoc-Val-Phe-OH loaded on resin for 10 min twice and the coupling reagents for Fmoc-Gly-OH were next treated, without the transformation with gold catalysis. The peptide cleaved with 1% TFA in CH₂Cl₂ showed a single major peak in HPLC analysis. The mass spectra of the peptide obtained from this fraction showed the peak derived from desired Epoc-Val-Phe-OH (HRMS (ESI, pos): calcd. for C₃₁H₃₄N₃O₆ [M+H]⁺: 544.2442 found: 544.2440). The reaction procedure of each step was monitored with the HPLC analysis of the peptide cleaved from the small portion of resin (condition: **Table S2**, chart: **Figure S6**).


Table S2 HPLC method for monitoring the reaction procedure of the synthesis of Fmoc-Gly-Val-Phe-OH

Time (min)	Flow rate (mL/min)	H ₂ O with 0.1% TFA (%)	CH ₃ CN with 0.1% TFA (%)
0	1.0	95	5
5	1.0	95	5
10	1.0	53	47
35	1.0	53	47


(a) Before treatment with [Au]



(b) After treatment with [Au]



(c) After treatment with piperidine



(d) After coupling with Fmoc-Gly-OH






Figure S5 HPLC chart for the reaction for Epoc-Val-Phe-OH: (a) before treatment with gold catalyst, (b) after treatment with gold catalyst, (c) after treatment with piperidine, and (d) after coupling with Fmoc-Gly-OH. The peptides were identified based on the MS spectra of the collected fractions.

(a) Before treatment with piperidine



(b) After treatment with piperidine



(c) After coupling with Fmoc-Gly-OH




Figure S6 HPLC chart for the reaction for Epoc-Val-Phe-OH without gold catalysis (negative control): (a) before treatment with piperidine, (b) after treatment with piperidine, (c) after coupling with Fmoc-Gly-OH. The peptides were identified based on the MS spectra of the collected fractions.

3.2 Synthesis of branched peptides

The branched peptide **32** was synthesized from H-Gly-Trt(2-Cl)-resin (20.0 μmol , 0.33 mmol/g, 100-200 mesh, 1% DVB), following the standard procedure for Fmoc SPPS. The peptide chains were elongated by the treatment with protected amino acids (order: Fmoc-Tyr(*t*Bu)-OH, Fmoc-Ala-OH, Epoc-Lys(Fmoc)-OH, Fmoc-Phe-OH, Fmoc-Ser(*O**t*Bu)-OH, Boc-Gly-OH, 4.0 Eq), HOBt (4.0 Eq), HBTU (4.0 Eq) and DIPEA (8.0 Eq) in DMF (500 μL). After the coupling the resins were washed with CH_2Cl_2 (1 mL, 3 times) and DMF (1 mL, 3 times). The reaction completion of the coupling was monitored with Kaiser test, and the coupling was repeated when the reaction was not completed. Fmoc group was cleaved by the treatment with 20% piperidine/DMF for 10 min after each coupling.

The transformation of Epoc group was performed by the treatment of $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ (0.1 Eq, 100mg/mL stock solution in MeOH) in CH_2Cl_2 for 1 hour (1st) and 4 hours (2nd). After each treatment, the resins were washed with CH_2Cl_2 (1 mL, 3 times) and DMF (1 mL, 3 times). The reaction procedure was monitored with the HPLC analysis of the peptide cleaved from the small portion of resin. In this step, we used the cleavage cocktail containing thiol reagent (TFA/1-dodecanethiol/ $\text{CH}_2\text{Cl}_2 = 2/8/90$) to quench residual gold(III) catalysts absorbed on resin and avoid the transformation after cleavage. After the completion of transformation, the resin was treated with 20% piperidine/DMF for 10 minutes and the completion of the removal of Hmoc was monitored by the HPLC analysis. The peptide was further elongated in the same way as above mentioned (Fmoc-Glu-(*O**t*Bu)-OH, Fmoc-Trp(Boc)-OH, and Fmoc-Thr(*O**t*Bu)-OH).

The obtained peptide was cleaved from resin by the treatment with the cleavage cocktail (TFA/ H_2O /triisopropylsilane = 90/5/5) for 2 hours, and triturated in cold Et_2O to obtain the crude peptide. The peptide was purified with preparative HPLC (20 \times 250 mm Cosmosil 5C₁₈-AR-300 column from Nacalai Tesque (Kyoto, Japan)) was used with 8.0 mL/min flow rate, isocratic flow with 25% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ containing 0.1% TFA to obtain the branched peptide **32** (7.7 mg, 6.8 μmol , 34%, 99% pure).

Branched peptide **32**: HRMS (ESI, pos): calcd. for $\text{C}_{54}\text{H}_{73}\text{N}_{12}\text{O}_{16}$ $[\text{M}+\text{H}]^+$: 1145.5262 found: 1145.5265.




Figure S7 HPLC chart of branched peptide **32** before (a) and after (b) purification. The condition for HPLC analysis was shown in **Table S3**.

The branched peptide **35** was synthesized from H-Gly-Trt(2-Cl)-resin (20.0 μmol , 0.33 mmol/g, 100-200 mesh, 1% DVB), following the standard procedure for Fmoc SPPS. The peptide chains were elongated by the treatment with protected amino acids (order: Fmoc-Arg(Pbf)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Epoc)-OH, Fmoc-Ser(*t*Bu)-OH, Fmoc-His(Trt)-OH, Boc-Ala-OH, 4.0 Eq), HOBt (4.0 Eq), HBTU (4.0 Eq) and DIPEA (8.0 Eq) in DMF (500 μL). After the coupling the resins were washed with CH_2Cl_2 (1 mL, 3 times) and DMF (1 mL, 3 times). The reaction completion of the coupling was monitored with Kaiser test, and the coupling was repeated when the reaction was not completed. Fmoc group was cleaved by the treatment with 20% piperidine/DMF for 10 min after each coupling and subsequent washing with DMF (1 mL, 5 times).

The transformation of Epoc group was performed by the treatment of $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ (0.1 Eq, 100mg/mL stock solution in MeOH) in CH_2Cl_2 for 1 hour (1st), 2 hours (2nd) and 2 hours (3rd). After each treatment, the resins were washed with CH_2Cl_2 (1 mL, 3 times) and DMF (1 mL, 3 times). The reaction procedure was monitored with the HPLC analysis of the peptide cleaved from the small portion of resin using the cleavage cocktail containing thiol reagent (TFA/1-dodecanethiol/ $\text{CH}_2\text{Cl}_2 = 2/8/90$). After the completion of transformation, the resin was treated

with 10% piperidine/DMF for 15 minutes \times 5 times and the completion of the removal of Hmoc was monitored by the HPLC analysis. The peptide was further elongated in the same way as above mentioned (Fmoc-Phe-OH, Fmoc-Trp(Boc)-OH, and Fmoc-Glu(OtBu)-OH).

The obtained peptide was cleaved from resin by the treatment with the cleavage cocktail (TFA/ethanedithiol/H₂O/triisopropylsilane = 89/1/5/5) for 2 hours, and triturated in cold Et₂O to obtain the crude peptide. The peptide was purified with preparative HPLC (20 \times 250 mm Cosmosil 5C₁₈-AR-300 column from Nacalai Tesque (Kyoto, Japan)) was used with 8.0 mL/min flow rate, isocratic flow with 25% CH₃CN/H₂O containing 0.1% TFA to obtain the branched peptide **35** (8.6 mg, 5.2 μ mol, 26% yield, 95% pure).

Branched peptide **35**: HRMS (ESI, pos): calcd. for C₇₀H₁₀₇N₂₁O₁₈S₂ [M+2H]²⁺: 796.8767 found: 796.8836.




Figure S8 HPLC chart of branched peptide **31** before (a) and after (b) purification. The condition for HPLC analysis was shown in **Table S3**.



Table S3 HPLC method for the analysis of purity for branched peptides



Time (min)	Flow rate (mL/min)	H ₂ O with 0.1% TFA (%)	CH ₃ CN with 0.1% TFA (%)
0	1.0	95	5
5	1.0	95	5
30	1.0	40	60



4. References



- 1 A. Odriozola, M. Oiarbide and C. Palomo, *Chem. Eur. J.*, 2017, **23**, 12758–12762.
- 2 K. Sugimoto, K. Toyoshima, S. Nonaka, K. Kotaki, H. Ueda and H. Tokuyama, *Angew. Chem. Int. Ed.*, 2013, **52**, 7168–7171.
- 3 S. Meng, W. Zhong, W. Yao and Z. Li, *Org. Lett.*, 2020, **22**, 2981–2986.
- 4 S. K. Fehler, G. Pratsch, C. Östreicher, M. C. D. Fürst, M. Pischetsrieder and M. R. Heinrich, *Tetrahedron*, 2016, **72**, 7888–7893.



5. NMR spectra


















JEOL
Solutions for Innovation

```


Filename = TX-BSC-3-167-4.jdf
Author = delta
Experiment = single_pulse.ex2
Sample_Id = S8348774
Solvent = CHLOROFORM-D
Creation_Time = 16-JAN-2021 08:56:59
Revision_Time = 11-MAY-2021 19:45:48
Current_Time = 11-MAY-2021 19:47:37

Comment = single_pulse
Data_Format = 1D_COMPLEX
Dim_Size = 13107
Dim_Title = 18
Dim_Units = [ppm]
Dimensions = X
Site = EXX 400P
Spectrometer = DELTA2_NMR

Field_Strength = 9.20197068[T] (390[MHz])
X_Acq_Duration = 2.228224[s]
X_Domain = 18
X_Freq = 391.78655441[MHz]
X_Offset = 5[ppm]
X_Points = 14384
X_Prescans = 1
X_Resolution = 0.44879791[Hz]
X_Sweep = 7.35294118[kHz]
Irr_Domain = 18
Irr_Freq = 391.78655441[MHz]
Irr_Offset = 5[ppm]
Irr_Domain = 18
Irr_Freq = 391.78655441[MHz]
Irr_Offset = 5[ppm]
Clipped = FALSE
Scans = 16
Total_Scans = 16

Relaxation_Delay = 2.5[s]
Recvr_Gain = 36
Temp_Get = 25[dc]
X_90_Width = 9[us]
X_Acq_Time = 2.228224[s]
X_Angle = 45[deg]
X_Atn = 0.5[db]
X_Pulse = 4.5[us]
Irr_Mode = Off
Tri_Mode = Off
Dante_Preset = FALSE
Initial_Wait = 1[s]
Repetition_Time = 4.728224[s]

```



JEOL
Solutions for Innovation

```


Filename = TX-BSC-3-167-carbon-6.jdf
Author = delta
Experiment = single_pulse_dec
Sample_Id = S8348023
Solvent = CHLOROFORM-D
Creation_Time = 16-JAN-2021 09:04:06
Revision_Time = 11-MAY-2021 19:50:21
Current_Time = 11-MAY-2021 19:52:01

Comment = single_pulse_decoupled_gat
Data_Format = 1D_COMPLEX
Dim_Size = 26214
Dim_Title = 13C
Dim_Units = [ppm]
Dimensions = X
Site = EXX 400P
Spectrometer = DELTA2_NMR

Field_Strength = 9.20197068[T] (390[MHz])
X_Acq_Duration = 1.06430464[s]
X_Domain = 13C
X_Freq = 98.51479726[MHz]
X_Offset = 100[ppm]
X_Points = 32768
X_Prescans = 4
X_Resolution = 0.9398061[Hz]
X_Sweep = 30.78817734[kHz]
Irr_Domain = 18
Irr_Freq = 391.78655441[MHz]
Irr_Offset = 5[ppm]
Clipped = FALSE
Scans = 121
Total_Scans = 121

Relaxation_Delay = 2[s]
Recvr_Gain = 54
Temp_Get = 25[dc]
X_90_Width = 9.25[us]
X_Acq_Time = 1.06430464[s]
X_Angle = 30[deg]
X_Atn = 4[db]
X_Pulse = 3.08333333[us]
Irr_Atn_Dec = 17.692[db]
Irr_Atn_Moe = 17.692[db]
Irr_Noise = WALTZ
Decoupling = TRUE
Initial_Wait = 1[s]
Noe = TRUE
Noe_Time = 2[s]
Repetition_Time = 3.06430464[s]

```



JEOL
Solutions for Innovation

```


Filename = TX-BSC-3-073_PROTON-7.jdf
Author = delta
Experiment = single pulse.ex2
Sample_Id = TX-BSC-3-073
Solvent = CHLOROFORM-D
Creation_Time = 29-MAR-2021 18:09:05
Revision_Time = 11-MAY-2021 20:00:11
Current_Time = 11-MAY-2021 20:01:43

Data_Format = 1D_COMPLEX
Dim_Size = 13107
Dim_Title = 1H
Dim_Units = [ppm]
Dimensions = X
Site = KMX 400P
Spectrometer = DELTA2_NMR

Field_Strength = 9.20197068[T] (390[MHz])
X_Acq_Duration = 2.228224[s]
X_Domain = 1H
X_Freq = 391.7865441[MHz]
X_Offset = 5[ppm]
X_Points = 16384
X_Prescans = 1
X_Resolution = 0.44878791[Hz]
X_Sweep = 7.35294118[kHz]
Irr_Domain = 1H
Irr_Freq = 391.7865441[MHz]
Irr_Offset = 5[ppm]
Tri_Domain = 1H
Tri_Freq = 391.7865441[MHz]
Tri_Offset = 5[ppm]
Clipped = FALSE
Scans = 16
Total_Scans = 16

Relaxation_Delay = 2.5[s]
Recvr_Gain = 38
Temp_Get = 460.0[degC]
X_90_Width = 11.45[us]
X_Acq_Time = 2.228224[s]
X_Angle = 45[deg]
X_Atn = 0.5[dB]
X_Pulse = 5.725[us]
Irr_Mode = Off
Tri_Mode = Off
Dance_Preset = FALSE
Initial_Wait = 1[s]
Repetition_Time = 4.728224[s]

```



JEOL
Solutions for Innovation

```



Filename = TX-BSC-3-073_CARBON-11.jdf
Author = delta
Experiment = single pulse dec
Sample_Id = TX-BSC-3-073
Solvent = CHLOROFORM-D
Creation_Time = 29-MAR-2021 23:23:31
Revision_Time = 11-MAY-2021 20:10:18
Current_Time = 11-MAY-2021 20:10:43



Data_Format = 1D_COMPLEX
Dim_Size = 104856
Dim_Title = 13C
Dim_Units = [ppm]
Dimensions = X
Site = KMX 400P
Spectrometer = DELTA2_NMR


Field_Strength = 9.20197068[T] (390[MHz])
X_Acq_Duration = 1.06430464[s]
X_Domain = 13C
X_Freq = 98.51479726[MHz]
X_Offset = 100[ppm]
X_Points = 32768
X_Prescans = 4
X_Resolution = 0.93958061[Hz]
X_Sweep = 30.78817734[kHz]
Irr_Domain = 1H
Irr_Freq = 391.7865441[MHz]
Irr_Offset = 5[ppm]
Clipped = FALSE
Scans = 6144
Total_Scans = 6144

Relaxation_Delay = 2[s]
Recvr_Gain = 52
Temp_Get = 460.0[degC]
X_90_Width = 9[us]
X_Acq_Time = 1.06430464[s]
X_Angle = 30[deg]
X_Atn = 4[dB]
X_Pulse = 3[us]
Irr_Atn_Dec = 17.692[dB]
Irr_Atn_Noise = 17.692[dB]
Irr_Noise = WALTZ
Decoupling = TRUE
Initial_Wait = 1[s]
Noe = TRUE
Noe_Time = 2[s]
Repetition_Time = 3.06430464[s]

```









JEOL
Solutions for Innovation

Filename	= TX-BSC-4-022_PROTON-12.jdf
Author	= delta
Experiment	= single_pulse.ex2
Sample Id	= TX-BSC-4-022
Solvent	= CHLOROFORM-D
Creation Time	= 4-MAR-2021 03:20:51
Revision Time	= 11-MAY-2021 20:47:23
Current Time	= 11-MAY-2021 20:47:36
Data Format	= 1D_COMPLEX
Dim Size	= 13107
Dim Title	= 1H
Dim Units	= [ppm]
Dimensions	= X
Site	= KIX 400P
Spectrometer	= DELTA2_NMR
Field Strength	= 9.20197068[T] (390[MHz])
X_Acq Duration	= 2.228224[s]
X_Domain	= 1H
X_Freq	= 391.7865441[MHz]
X_Offset	= 5[ppm]
X_Points	= 16384
X_Prescans	= 1
X_Resolution	= 0.44878791[Hz]
X_Sweep	= 7.35294118[kHz]
Irr_Domain	= 1H
Irr_Freq	= 391.7865441[MHz]
Irr_Offset	= 5[ppm]
Irr_Domain	= 1H
Irr_Freq	= 391.7865441[MHz]
Irr_Offset	= 5[ppm]
Clipped	= FALSE
Scans	= 16
Total Scans	= 16
Relaxation Delay	= 2.5[s]
Recvr Gain	= 34
Temp Get	= 21.9[dc]
X_90_Width	= 11.45[us]
X_Acq Time	= 2.228224[s]
X_Angle	= 45[deg]
X_Attn	= 0.5[dB]
X_Pulse	= 5.725[us]
Irr_Mode	= Off
Tri_Mode	= Off
Dance Presat	= FALSE
Initial Wait	= 1[s]
Repetition Time	= 4.728224[s]



JEOL
Solutions for Innovation

Filename	= TX-BSC-4-022_CARBON-10.jdf
Author	= delta
Experiment	= single_pulse_dec
Sample Id	= TX-BSC-4-022
Solvent	= CHLOROFORM-D
Creation Time	= 4-MAR-2021 06:50:42
Revision Time	= 11-MAY-2021 20:50:12
Current Time	= 11-MAY-2021 20:50:39
Data Format	= 1D_COMPLEX
Dim Size	= 26214
Dim Title	= 13C
Dim Units	= [ppm]
Dimensions	= X
Site	= KIX 400P
Spectrometer	= DELTA2_NMR
Field Strength	= 9.20197068[T] (390[MHz])
X_Acq Duration	= 1.06430464[s]
X_Domain	= 13C
X_Freq	= 98.51479726[MHz]
X_Offset	= 100[ppm]
X_Points	= 32768
X_Prescans	= 4
X_Resolution	= 0.93958061[Hz]
X_Sweep	= 30.78817734[kHz]
Irr_Domain	= 1H
Irr_Freq	= 391.7865441[MHz]
Irr_Offset	= 5[ppm]
Clipped	= FALSE
Scans	= 4096
Total Scans	= 4096
Relaxation Delay	= 2[s]
Recvr Gain	= 34
Temp Get	= 21.6[dc]
X_90_Width	= 9[us]
X_Acq Time	= 1.06430464[s]
X_Angle	= 30[deg]
X_Attn	= 4[db]
X_Pulse	= 3[us]
Irr_Attn_Dec	= 17.692[db]
Irr_Attn_Noise	= 17.692[db]
Irr_Noise	= WALTZ
Decoupling	= TRUE
Initial Wait	= 1[s]
Noe	= TRUE
Noe Time	= 2[s]
Repetition Time	= 3.06430464[s]

